Urinary Activin A as Apredictive Marker for Assessement of Acute Kidney Injury Severity in Patient Admitted at Assuit University Hospital
NCT ID: NCT06188533
Last Updated: 2024-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
70 participants
OBSERVATIONAL
2024-03-01
2026-12-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of AI Prediction Models in Prediction of Acute Kidney Injury in Critical Patients
NCT06857188
Acute Kidney Injury and Acute Kidney Disease in COVID-19
NCT04353583
Evaluation of Novel Biomarkers From Acutely Ill Patients at Risk for Acute Kidney Injury
NCT01209169
Platelets to Albumin Ratio for Prediction of Acute Kidney Injury in Patients Admitted to the Intensive Care Unit
NCT06554977
Acute Kidney Injury in Neonatal ICU in Assuit University
NCT07083284
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Estimates of AKI prevalence range from \<1% to 66%. These variations can be explained by not only population differences but also inconsistent use of standardized AKI classification criteria. The aetiology and incidence of AKI also differ between high-income and low-to-middle-income countries.(1)
* It can be presented in different stages according to AKIN classification (stage l (Increase in serum creatinine ≥0.3md/dl (≥26.4μmol/l) or increase to \>150% to 200% (1.5 fold to 2 fold) from baseline , and urine output (\<0.5 ml/kg/h for \>6 h ))
* stage ll (Increase to \>200% to 300% (\>2 fold to 3 fold) from baseline) , and urine output (\<0.5 ml/kg/h for \>12 h ))
* stage lll(Increase in serum creatinine to \>300% (\>3 fold) from baseline, or serum creatinine \>4.0mg/dl (\>354μmol/l) with acute increase of atleast 0.5mg/dl ) Urine output(\<0.3ml/kg/hr for 24 hours, or anuria for 12 hours). (2)
* In ischemic kidney, there is acytokine belong to the transforming growth factor (TGF)-B ( Activin A) that regulates the growth and differantiation of cell in variuos organs was significantly increasd in ischemic kidney . (3)
* level of Activin A in urine correlate to the severity of the acute kidney injury (AKI), as the level of urinary Activin A in first stages of acute kidney injury is less than the second and third stages . (4)
* so follow up of urinary Activin A in patients with acute kidney injury can be avery useful biomarker for assessement of severity of acute kidney injury. (4)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Urinary activin A in AKI
Urinary activin A in AKI patient
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kamal mahmoud mohamed amin
Principal investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Urinary activin A in AKI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.